Ignite Creation Date:
2024-06-16 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 3:30 PM
Study NCT ID:
NCT06431529
Status:
RECRUITING
Last Update Posted:
2024-05-28
First Post:
2024-05-22
Brief Title:
A Study of Tumor Neoantigen-specific T Cells in the Treatment of Advanced Solid Tumors
Sponsor:
JIANG LONGWEI
Organization:
Jinling Hospital China
Study Overview
Official Title:
Exploratory Clinical Study of Tumor Neoantigen-specific T Cells in the Treatment of Advanced Solid Tumors
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
Neoantigen-T
Brief Summary:
The goal of this clinical trial is to learn if tumor neoantigen-specific T cells can treat patients with advanced solid tumors The main questions it aims to answer are
Evaluate the safety of intravenous infusion of tumor neoantigen-specific T cells in the treatment of advanced solid tumors such as ovarian cancer non-small cell lung cancer and colorectal cancer
To evaluate the effectiveness of intravenous infusion of tumor neoantigen-specific T cells in the treatment of advanced solid tumors such as ovarian cancer non-small cell lung cancer and colorectal cancer and to study its immunological properties in patients
Evaluate the safety of intravenous infusion of tumor neoantigen-specific T cells in the treatment of advanced solid tumors such as ovarian cancer non-small cell lung cancer and colorectal cancer
To evaluate the effectiveness of intravenous infusion of tumor neoantigen-specific T cells in the treatment of advanced solid tumors such as ovarian cancer non-small cell lung cancer and colorectal cancer and to study its immunological properties in patients
Detailed Description:
In this open single-armed study selected patients with advanced solid tumor confirmed by Histopathology will be received tumor neoantigen specific T cells treatment First their tumor specimen will be collected from surgery or puncturethen their PBMC will be separated by blood cell separator This cells will be cultured and selected in GMP laboratory to make tumor neoantigen specific T cells The tumor neoantigen specific T cells will be infused intravenous into patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None